DSIP vs FOXO4-DRI
DSIP and FOXO4-DRI are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: DSIP is nonapeptide (9 residues), strongly acidic, while FOXO4-DRI is 46-residue all-d retro-inverso peptide — different molecular classes with different handling consequences; they call for different primary diluents (sterile or bacteriostatic water versus sterile water (usp grade)); their leading degradation routes differ (tryptophan photo-oxidation for DSIP, deamidation at the asn-gly motif in the sequence for FOXO4-DRI), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
DSIP — origin
DSIP was isolated in the 1970s from the cerebral venous blood of rabbits in slow-wave sleep, in one of the more unusual isolation efforts in neuropeptide research. The name records the assay it was found by rather than a settled mechanism — its physiological role remains debated in the literature.
FOXO4-DRI — origin
FOXO4-DRI was designed in the laboratory of Peter de Keizer (Erasmus University Medical Center) and published in Cell in 2017 (Baar et al.). It mimics the region of the transcription factor FOXO4 that binds p53, but is built from D-amino acids in reversed order — a retro-inverso design that keeps the side-chain layout while making the backbone unrecognisable to proteases. A cationic, arginine-rich tail derived from the HIV-TAT cell-penetrating sequence carries it into cells.
DSIP research themes
Investigated for effects on slow-wave sleep in the models that gave the peptide its name.
Studies have examined interactions with stress-axis signalling.
Explored in preclinical models of oxidative and stress-related neuronal injury.
Notably, decades of work have not converged on an accepted receptor or mechanism — a recurring theme in the literature.
FOXO4-DRI research themes
The founding study showed that senescent cells rely on FOXO4 holding p53 in the nucleus. Interfering with that interaction caused p53 nuclear exclusion and intrinsic apoptosis selectively in senescent cells in culture (Baar et al., Cell 2017).
The same study examined doxorubicin-induced senescence, fast-ageing XpdTTD/TTD mice and naturally aged mice, reporting changes in fur density, fitness and renal markers.
Studied in hydrogen-peroxide-induced senescent TM3 Leydig cells and aged mice for effects on the testicular microenvironment (Zhang et al., Aging 2020).
At 25 µM in vitro it removed a large share of late-passage (senescent-enriched) human chondrocytes while sparing early-passage cells, without improving cartilage-forming capacity (Huang et al., Front Bioeng Biotechnol 2021).
DSIP handling
- Store and handle protected from light at all stages, including during reconstitution.
- Keep working solutions at or above neutral pH; acidification risks precipitation near the isoelectric point.
- Avoid prolonged storage of reconstituted material — the isomerisation route is slow but cumulative.
FOXO4-DRI handling
- Let the vial reach room temperature before opening.
- Add diluent gently down the vial wall and swirl; do not vortex.
- Use low-bind polypropylene rather than glass for dilutions — the cationic tail adsorbs to glass.
- Protect solutions from light.
Both third-party tested
Every Popular Peptides batch of DSIP and FOXO4-DRI is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
DSIP reference
Related comparisons
DSIP and FOXO4-DRI are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.